Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors
- 8 November 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 60 (2), 203-209
- https://doi.org/10.1007/s00280-006-0362-y
Abstract
MAC-321 is a novel taxane that has demonstrated exceptional activity in human xenograft models when administered intravenously and orally. Preclinical studies of MAC-321 have shown antitumor activity in MDR-expressing and paclitaxel-resistant tumors. This phase I dose escalation study was performed to determine the safety, tolerability, and pharmacokinetic profile of orally administered MAC-321 given once every 21 days. Preliminary antitumor activity of MAC-321 was also examined.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of Epothilone B Analog in Advanced Soft Tissue Sarcoma: A Phase II Study of the Phase II ConsortiumJournal of Clinical Oncology, 2005
- Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast CancerJournal of Clinical Oncology, 2005
- Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancerAnnals of Oncology, 2005
- A Phase I and Pharmacokinetic Study of BAY59: A Novel TaxaneOncology, 2004
- Mechanisms of Cancer Drug ResistanceAnnual Review of Medicine, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2000
- Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding proteinJournal of Molecular Biology, 1999
- Optimal use of docetaxel (Taxotere®)Anti-Cancer Drugs, 1996
- Mechanism of action of taxolTrends in Pharmacological Sciences, 1992